In8bio, Inc. (INAB) — 10-Q Filings

10-Q Filings (6)

• IN8BIO Narrows Q3 Loss Amid Cash Crunch, Going Concern Doubts Linger — Nov 6, 2025 Risk: high
  IN8BIO, INC. (INAB) reported a net loss of $3.854 million for the three months ended September 30, 2025, a significant improvement from the $7.086 million net l
• IN8BIO Narrows Q2 Loss Amid R&D Spend Shift — Aug 7, 2025 Risk: high
  IN8BIO, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage biotechnology status. The company's net lo
• IN8BIO, INC. Files Q1 2025 10-Q — May 7, 2025 Risk: medium
  IN8BIO, INC. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Incysus Therapeutics, Inc., is involved in biologic
• IN8BIO, INC. Files Q3 2024 10-Q, Details Equity and Warrant Activity — Nov 12, 2024 Risk: medium
  IN8BIO, INC. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations, including detai
• IN8BIO, INC. Q2 2024 10-Q Filing — Aug 8, 2024 Risk: medium
  IN8BIO, INC. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the first six months of 2024 and the
• IN8BIO, INC. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
  IN8BIO, INC. (INAB) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. IN8BIO, INC. filed a 10-Q for the period ending March 31, 2024. The filing cove

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX